A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis

Trial Profile

A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Abrilumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 02 Feb 2017 Planned End Date changed from 1 Nov 2019 to 1 Apr 2018.
    • 29 May 2016 This trial has been terminated in Denmark.
    • 03 Mar 2016 Planned End Date changed from 1 Mar 2019 to 1 Nov 2019, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top